Navigation Links
Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines
Date:6/13/2008

CHAPEL HILL, N.C., June 13 /PRNewswire/ -- Best Practices, LLC's latest benchmarking study explains how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines.

Particular attention is paid to CI information sources, what is being collected, and how CI groups work within legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department's ability to deliver results.

Savvy CI leaders employ multiple, even overlapping, secondary data sources and triangulate from them to develop the most accurate information and projections, described in the newly published study, "Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines" by Best Practices, LLC. Click here for complimentary download: http://www3.best-in-class.com/dr316.htm

Executives from many of the top 50 pharmaceutical companies have found that one of the most useful tools that they have at their disposal when it comes to gaining information and benchmarking best practices about competitive intelligence is the Best Practices Database. To view a list of just some of the documents pertaining to competitive intelligence click on this link: http://www3.best-in-class.com/dr316.htm

Best Practices Database covers many key functionality areas pertaining to Pharma Industry such as:
-- Resources and strategies required to gain crucial market access

-- Creating blockbusters in an increasingly competitive marketplace

-- Publications strategies that give credibility and increase reputation

-- Key to building effective brand teams

-- Case studies for successful re-launches

-- Strategies for successful
'/>"/>

SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... OAKLAND, Calif., September 22, 2014 Patients who were treated ... a hemorrhagic stroke were significantly more likely to survive ... published today in JAMA Neurology . This study ... that the use of cholesterol-lowering statins can improve survival ... by a constriction or obstruction of a blood vessel ...
(Date:9/22/2014)... 22, 2014 Research and ... of the "Global Biotechnology Reagents Market 2014-2018" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents are chemical ... system to detect and examine another substance to ... in laboratories to prepare, collect, and examine specimens ...
(Date:9/22/2014)... of circulating tumor cells (CTCs) in a mouse model ... in several groups of CTCs, including significant differences from ... to generate metastases. In their study reported in ... investigators from the Massachusetts General Hospital (MGH) Cancer Center ... unexpected factors that may prove to be targets for ...
(Date:9/22/2014)... way to create a highly sensitive chemical sensor based ... have unique electronic properties that the researchers were able ... by 300 times. , The study is available online ... , Amin Salehi- Khojin, asst professor of mechanical and ... student and Bijandra Kumar, post doc where they are ...
Breaking Biology Technology:Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Massachusetts General study reveals gene expression patterns in pancreatic CTCs 2Massachusetts General study reveals gene expression patterns in pancreatic CTCs 3Graphene imperfections key to creating hypersensitive 'electronic nose' 2
... KENILWORTH and WHITEHOUSE STATION, N.J., April 25 ,Schering-Plough/MERCK ... letter from the U.S. Food and Drug Administration,(FDA) ... montelukast for,the treatment of allergic rhinitis symptoms in ... New Drug Application filing for loratadine/montelukast was accepted,by ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced today that it ... that the Company is not in,compliance with the $1.00 ... Global Market pursuant to Marketplace Rule 4450,(a)(5). This notification, ... is a standard communication when the bid price of ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, announced,today that it ... Conference being held April 30 - May 2, ... Zwanziger, Chief Executive Officer, will,attend. His presentation is ...
Cached Biology Technology:Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 2Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 3Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3
(Date:9/23/2014)... Company has secured $21 million in a Series C ... the Company,s cancer immunotherapy pipeline and advance its lead ... the round, with participation from Majuven and all existing ... Harbinger Venture Capital. , Eureka is engaged in ... mimic the functions of a T cell receptor, a ...
(Date:9/23/2014)... of scientists has identified a gene mutation that ... which the bone marrow fails to produce normal ... which three generations had blood disorders, the researchers ... telomeres, chromosomal structures with crucial roles in normal ... help suggest future molecular-based treatments that bypass the ...
(Date:9/23/2014)... the development of animals and plants. The central problem ... translated in a reliable manner to give specific spatial ... of stripe formation is a classic paradigm in developmental ... the French flag, is caused by a gradient of ... low concentrations of the morphogen a "blue", "white" or ...
Breaking Biology News(10 mins):Gene mutation discovered in blood disorder 2Recreating the stripe patterns found in animals by engineering synthetic gene networks 2
... the cacao genome is complete, a consortium of academic, ... scientists performed much of the sequencing work, which is ... website of the Cacao Genome Database project. Despite ... Inc., Cacao Genome Database scientists say one of their ...
... , BOSTON (9-15-10) -- A team led by Boston ... four-year grant from the National Institutes of Health to ... could lead to individual genome sequencing for less than ... on an initial, $2.2 million NIH grant and led ...
... 15 September 2010 -- The European Society for Medical Oncology ... the advancement of medical research. The awards will be presented ... 35th ESMO Congress, to take place from 8-12 October in ... the 2010 ESMO Award for his key role in the ...
Cached Biology News:Chocolate farmers could benefit from newly sequenced cacao genome 2Chocolate farmers could benefit from newly sequenced cacao genome 3Chocolate farmers could benefit from newly sequenced cacao genome 4BU team wins $4.1M genome grant 2Top cancer specialists receive ESMO awards 2Top cancer specialists receive ESMO awards 3Top cancer specialists receive ESMO awards 4
... synthetic peptide whose sequence is from the C-terminal end of the mouse ... from amino acids 429 to 448 of RAR*. The sequence of ... V - S - P - S - S - V - ... Q - S - P - L - L - Q ...
... The ELx50 is a fast and ... equipped with our patented Dual-ActionTM 16-channel manifold. ... of the dispense and aspiration manifolds for ... 96- and 384-well formats. The problem of ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Biology Products: